ascopubs.org

Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients

Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population Adj PD-1 therapy did not improve ...

Prospective Multicenter Registry Study Reports High Local Tumor Control Following Resection with GammaTile® in Newly Diagnosed Brain Metastases

GT Medical Technologies, Inc., a company focused on improving the lives of patients with brain tumors, today announced a publication of prospective, multicenter Phase IV data from the ongoing ...
WIBC 93.1 FM

Sleep Duration Directly Impacts Atrial Fibrillation Risk, Study Finds

Atrial fibrillation is the most common form of heart rhythm disorder and is linked to serious complications, including stroke and heart failure. While earlier research pointed to a possible ...

CereVasc, Inc. Announces Publication of A Multi-Center Study Evaluating the eShunt® System in the Treatment of Patients with NPH

CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, today ...

Study identifies long-term health risks in testicular cancer survivors treated with contemporary chemotherapy

A large, multi-center study published online in the Journal of the National Comprehensive Cancer Network (JNCCN) provides new insight into the long-term health effects of contemporary chemotherapy ...
ascopubs.org

Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK)

This multicenter, prospective study (ClinicalTrials.gov identifier: NCT04703153) enrolled patients across the United States and Singapore. Patients were tested with tissue NGS, LHM, and G360 ctDNA.

Adagio Medical (ADGM) announces successful results from US cardiac ablation feasibility study

Adagio Medical Holdings Inc. (NASDAQ:ADGM) is one of the best up and coming penny stocks to buy. On February 4, Adagio Medical Holdings announced the publication of results from its US Early ...
Medical Dialogues

Point-of-Care HemoTypeSC Shows 99.9 Percent Accuracy for Newborn Sickle Cell Screening: IJMR Study

India: A recent multicenter study published in the Indian Journal of Medical Research in September 2025 reports that the HemoTypeSC point-of-care (POC) test demonstrates 99.9% diagnostic accuracy in ...